Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial-Reference-Cited by-同舟云学术

Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial

Published:2024-07-02 Issue:1 Volume:150 Page:82-85
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

de Barros e Silva Pedro Gabriel Melo¹²³^ORCID,Macedo Ariane Vieira Scarlatelli¹²^ORCID,Bronhara Bruna¹,Damiani Lucas Petri¹⁴^ORCID,Mazza Barbosa Lilian¹,Lopes Nathália Rodrigues¹,Suiama Mayra Akimi¹,Antunes Murillo O.⁵^ORCID,Gonçalves Mariana Raquel⁵,Gebara Otávio Celso Eluf⁶^ORCID,de Aquino Martins Priscilla⁷,Ribeiro Mariana Galvão⁸^ORCID,de Moura Xavier de Moraes João Batista⁹,Aguiar Valéria Cristina Resende¹⁰,Cavalcanti Alexandre B.³¹¹^ORCID,Rosa Regis G.¹¹¹²^ORCID,Berwanger Otavio⁴¹³^ORCID,Veiga Viviane C.¹¹¹⁴,Azevedo Luciano C.P.¹¹¹⁵,Ramacciotti Eduardo^ORCID,Granger Christopher B.^ORCID,Alexander John H.¹⁶^ORCID,Avezum Alvaro¹⁷,Lopes Renato D.¹¹⁶,

Affiliation:

1. Brazilian Clinical Research Institute, São Paulo, Brazil (P.G.M.d.B.S., A.V.S.M., B.B., L.P.D., L.M.B., N.R.L., M.A.S., R.D.L.).

2. Hospital Samaritano Paulista, São Paulo, Brazil (P.G.M.d.B.S., A.V.S.M.).

3. HCOR Research Institute, São Paulo, Brazil (P.G.M.d.B.S., A.B.C.).

4. Academic Research Organization (ARO)–Hospital Israelita Albert Einstein, São Paulo, Brazil (L.P.D., O.B.).

5. Hospital Universitário São Francisco de Assis na Providência de Deus and Universidade São Francisco, Bragança Paulista, Brazil (M.O.A., M.R.G.).

6. Dasa-Hospital Santa Paula, São Paulo, Brazil (O.C.E.G.).

7. CENDERS–Vitoria Clinical Research Institute, Serra, Brazil (P.d.A.M.).

8. Hospital de Amor, Barretos, Brazil (M.G.R.).

9. Hospital Agamenon Magalhães, Recife, Brazil (J.B.d.M.X.d.M.).

10. Hospital e Maternidade Christóvão da Gama, DASA, Santo André, Brazil (V.C.R.A.).

11. Brazilian Research in Intensive Care Network (A.B.C., R.G.R., V.C.V., L.C.P.A.).

12. Hospital Moinhos de Vento, Porto Alegre, Brazil (R.G.R.).

13. George Institute for Global Health UK at Imperial College, London, UK (O.B.).

14. BP–A Beneficência Portuguesa de São Paulo, Brazil (V.C.V.).

15. Hospital Sírio Libanês Research and Education Institute, São Paulo, Brazil (L.C.P.A.).

16. Duke Clinical Research Institute, Duke University, Medical Center, Durham, NC (J.H.A., R.D.L.).

17. International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil (A.A.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference5 articles.

1. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

2. Apixaban for Extended Treatment of Venous Thromboembolism

3. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

4. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

5. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19